Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
sub-chronic toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Similar to OECD TG 408, but without recovery period.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1989
Report date:
1989

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
Deviations:
yes
Remarks:
; no recovery period
Principles of method if other than guideline:
similar/equivalent to OECD TG 408, but without recovery period.
GLP compliance:
yes
Limit test:
no

Test material

Constituent 1
Reference substance name:
Bis(hydroxylammonium) sulphate
EC Number:
233-118-8
EC Name:
Bis(hydroxylammonium) sulphate
Cas Number:
10039-54-0
IUPAC Name:
bis(hydroxyammonium) sulfate
Details on test material:
- Name of test material (as cited in study report): Hydroxylammoniumsulfat (HAS)
- Analytical purity: >= 99 %
- Lot/batch No.: 84/389
- Stability under test conditions: was ensured during the study period

Test animals

Species:
rat
Strain:
Wistar
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Dr. Karl Thomae GmbH, Biberach a.d. Riss, Germany
- Age at study initiation: 42 days
- Average weight at study initiation: males ca. 117 g; females ca. 136 g
- Housing: individually in V2A wire mesh cages, type DK III (Becker & Co. Castrop-Rauxel, Germany)
- Diet: Kliba-Haltungsdiaet Ratte/Maus/Hamster 343 Mehl (Klingentalmuehle AG, Kaiseraugst, Switzerland), ad libitum
- Water: Milli-Q-Reinstwasser, ad libitum
- Acclimation period: 7 days

ENVIRONMENTAL CONDITIONS
- Temperature: 20 - 24 °C
- Humidity: 30 - 70 %
- Air changes: fully air-conditioned rooms
- Photoperiod: 12 hrs dark / 12 hrs light

Administration / exposure

Route of administration:
oral: drinking water
Vehicle:
other: Mili-Q extra pure water
Details on oral exposure:
In a subchronic oral toxicity study similar to OECD TG 408 (but without recovery period), Hydroxylammonium sulfate was administered to 60 Wistar rats (30 males and 30 females ) via the drinking water (in Milli-Q extra pure water) for 90 consecutive days. For comparison, one group of untreated animals (10 males and 10 females) was used as control.
The doses in the drinking water were 10 ppm (test group 1), 50 ppm (test group 2) and 250 ppm (test group 3). The doses administered corresponded to a mean daily test substance intake of approx. 0.9, 4 and 21 mg/kg body weight. The average daily food intake in mg/kg bw was calculated for each animal at the time intervals when the water consumption was determined.
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
For homogeneity and concentration control analyses, each samples of all concentrations were drawn at the start of the study, after 6 weeks and towards at the end of the administration period after 12 weeks of the study.
The analysis of the amount of the test material in the drinking water was determined by photometry.
Duration of treatment / exposure:
3 months
Frequency of treatment:
ad libitum
Doses / concentrations
Remarks:
Doses / Concentrations:
0, 10, 50, 250 ppm, corresponding to approx. 0.9, 4 and 21 mg/kg bw/day
Basis:
nominal in water
No. of animals per sex per dose:
10 animals per sex per dose
Control animals:
yes, concurrent vehicle
Details on study design:
The preparation of the test material in the drinking water was conducted twice weekly (on tuesdays and fridays). The test material was mixed with the water and then subsequently stirred for 10 minutes to ensure homogenization. The bottling was conducted with a fully automatized dosage apparatus (Fortuna Optimat MP).

Examinations

Observations and examinations performed and frequency:
- The animals were inspected twice daily for mortality/moribundity (monday to friday) and once daily on saturday, sunday and on public holidays.
- Feed consumption, drinking water consumption and body weight were determined once a week.
- The state of health was checked each day, and when the animals were weighed, they were additionally inspected and palpated.
- Before the beginning of test substance administration and toward the end of the study, ophthalmological examinations were carried out in the animals of the control and 250 ppm groups.

- Urine was collected for urinalyses 29 and 78 days after the beginning of administration.
The following parameters were determined semiquantitatively in urine using test stripes and a reflection photometer (Clini-Tek, Ames, Frankfurt, Germany):
- pH
- total protein
- glucose
- ketones
- bilirubin
- blood
- nitrite
- urobilinogen
The sediment analysis was conducted by microscopy.

- Blood samples were taken for clinicochemical and hematological examinations 36 and 85 days after the beginning of administration. Blood was taken in the morning out of non-fasted animals.
The following clinico-chemical/hematological parameters were determined:

Hematological examinations:
The following parameters were determined in blood using a particle counter (S Plus model, by Coulter, Krefeld, Germany):
- leukocytes
- erythrocytes
- hemoglobin
- hematocrit
- mean corpuscular volume
- mean corpuscular hemoglobin
- mean corpuscular hemoglobin concentration
- platelets
- Heinz-bodies
- methaemoglobin
The data obtained were transferred to a computer (VAX 11/780; supplied by DEC, Munich, FRG). The differential blood count was evaluated visually. The data were transferred to the computer.

Clotting analyses:
The clotting analyses were carried out using a ball coagulometer (KC 10 model, by Amelung, Lemgo, Germany) and the results transferred off-line to the computer.
The following parameter was determined:
- thromboplastin time (Hepato Quick's test)

Clinicochemical examinations:
An automatic analyzer (Hitachi 737; by Boehringer, Mannheim, Germany) was used to examine the clinicochemical parameters. The values obtained were transferred to a computer (VAX 11/780; by DEC, Munich, Germany).
The following parameters were determined:
Enzymes
- alanine aminotransferase
- aspartate aminotransferase
- alkaline phosphatase

Blood chemistry:
- sodium
- potassium
- chloride
- inorganic phosphate
- calcium
- urea
- creatinine
- glucose
- total bilirubin
- total protein
- albumin
- globulins
- triglycerides
- cholesterol

Sacrifice and pathology:
At the end of the 3-month administration period, after a fasting period, all animals were sacrificed by decapitation after they had been anesthetized by CO2 and were assessed by gross pathology.
Subsequently, a histopathological examination was carried out.

The weight of the animals as well as the weights of liver, kidneys, adrenal glands, testes, brain and spleen from all animals sacrificed at scheduled dates was determined.
Subsequently the following organs or tissues were fixed in 4 % formaldehyde solution:
brain, pituitary gland, thyroid, thymus, trachea, lungs, heart, aorta, liver, spleen, kidneys, adrenal glands, pancreas, testes/ovaries, uterus, oesophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, bladder, mesenterial lymph nodes, peripheral nerve, sternum with medulla, all macroscopic changes.

After the organs had been fixed, processing, the examination by light microscopy and the evaluation of findings was performed in all animals of the control and the high dose groups. Additionally, the lung, liver and kidneys were examined fom all animals of any dose group.

In the liver, spleen of all dose groups as well as in the kidneys of high dose and control groups an iron analysis was also conducted.
Statistics:
For food consumption, water consumption, body weights, organ weights and substance consumption, as well as for clinico-chemical and haematological parameters means and standard deviations were calculated. Statistical analyses were conducted for body weight as well as for clinico-chemical and haematological parameters by using the Dunnett´s- test and the ANOVA analysis.
The individual parameters of the urinalysis were checked for statistical significance by using the chi square test.


Results and discussion

Results of examinations

Details on results:
Regarding mortality, general appearance and behaviour of the animals there was no difference between treated and untreated animals. No toxicologically relevant differences in mean feed consumption per animal/d or per kg bw/d as well as body weight and body weight development were detected in male and female rats. The following findings were obtained and assessed as substance-induced.

At 250 ppm, rats of both sexes showed dark coloration of the urine. This is considered to be due to the substance-related effects on the blood. The hematological examination revealed indications of an increased destruction of red blood cells.
At 250 ppm in both sexes and at 50 ppm in females there was a reduction of the erythrocytes and haemoglobin values. In addition there were an increase of the MCH values in both sexes at 250 ppm and in females at 50 ppm, furthermore reduced values of hematocrit in females and of the MCHC in males at 250 ppm. In males receiving 50 ppm, decreased counts of red blood cells and decreased values of haemoglobin were also apparent during the treatment period, although these did not attain statistical significance. These findings are considered to be related also to an increased decay of erythrocytes. The increase of the MCV, and reticulocyte counts at 250 ppm in males and females were assessed as sign of compensate increased erythropoiesis. As a consequence of an increased leaving of juvenile erythrocytes out of the bone marrow a reinforced polychromasia was seen dose-dependent at 250 and 50 ppm in both sexes. At 50 ppm, a slight increase of reticulocytes in male and female rats was noted, and moreover in females a marginal increase of the MCV values. Furthermore, an increase of bilirubin concentration in both sexes at 250 ppm was observed. In males and females receiving 50 ppm, increased values of bilirubin were also apparent during the treatment period, although these did not attain statistical significance. This finding appears to be due to the increased decay of erythrocytes. The elevated methaemoglobin concentration and the reinforced evidence of Heinz bodies in both sexes at 250 ppm are indicative for methaemoglobinemia. Increased absolute and relative spleen weights were seen at 250 ppm in male and female rats. Increase of relative liver weights were noted only in males. In males and females receiving 50 ppm, increased absolute and relative adrenal weights were noted.
Histopathological findings representing secondary effects to the anemia included increased hemosiderin deposits in the spleen and liver of both males and females given 250 ppm. At 50 ppm, moderate increased hemosiderin deposits in the spleen were revealed in both sexes. In addition, sinus dilatation together with congestion of the spleen were observed dosedependent in both sexes at 50 and 250 ppm. 10 ppm did not alter the blood parameters in rats of both sexes.

10 ppm (approx. 0.9 mg/kg bw/d):
No changes were found to be attributed to the test substance administered.

50 ppm (approx. 4 mg/kg bw/d):
- Clinical signs: none specific (m/f)
- Blood: ↓ RBC (f), (↓) RBC (m), ↓ Hb (f), (↓) Hb (m), ↑ MCV (f), ↑ MCH (f), ↑ polychromasia (m/f), ↑ RET (m/f), (↑) bilirubin (m/f)
- Effects on organs:
adrenal weight ↑, abs/rel (m/f); spleen: hemosiderin deposits (m/f), sinus dilatation together with congestion (2m/2f)

250 ppm (approx. 21 mg/kg bw/d):
- Clinical signs: dark coloration of the urine (m/f)
- Blood: ↓ RBC (m/f), ↓ Hb (m/f), ↓ HCT (f), ↓ MCHC (m), ↑ MCV (m/f), ↑ MCH (m/f), ↑ RET (m/f), ↑ Heinz bodies (m/f), ↑ MetHb (m/f), ↑ polychromasia (m/f), ↑ bilirubin (m/f)
- Effects on organs:
spleen: ↑ weight, abs (m/f), ↑ weight, rel (m), hemosiderin deposits (m/f), sinus dilatation together with congestion (10m/10f);
liver: ↑ weight, rel (m), hemosiderin deposits (m/f)

↑: statistically significant increase compared with controls; (↑): increase compared with controls, no statistically significant but possibly of toxicological relevance;
↓: statistically significant decrease compared with controls;
(↓): decrease compared with controls, no statistically significant but possibly of toxicological relevance;
m: male; f: female;
RBC: Erythrocyte count; Hb: Haemoglobin; HCT: Hematocrit; MCV: Mean corpuscular volume; MCH: Mean corpuscular haemoglobin; MCHC: Mean corpuscular haemoglobin concentration; MetHb: methaemoglobin; RET: Reticulocyte count

Effect levels

open allclose all
Dose descriptor:
NOAEL
Remarks:
systemic effects
Effect level:
> 0.9 mg/kg bw/day (nominal)
Sex:
male/female
Basis for effect level:
other: 10 ppm: no substance related effects on blood and organs
Dose descriptor:
NOAEL
Remarks:
local effects
Effect level:
>= 21 mg/kg bw/day (nominal)
Sex:
male/female
Basis for effect level:
other: no substance-related effects seen

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

Table 1: Hematology data for MetHB, reticulocytes and Heinz-Bodies on day 36 and 85, respectively

Males (n = 10)

MetHB: day 36

MetHB: day 85

reticulocytes: day 36

reticulocytes: day 85

Heinz-Bodies: day 36

Heinz-Bodies: day 85

0 ppm

0.0 ± 0.0

0.1 ± 0.1

19 ± 4

20 ± 8

0 ± 0

0 ± 0

10 ppm

0.0 ± 0.1

0.1 ± 0.2

17 ± 5

22 ± 5

0 ± 0

0 ± 0

50 ppm

0.0 ± 0.1

0.2 ± 0.2

25 ± 5

31 ± 10 *

0 ± 0

2 ± 2

250 ppm

0.2 ± 0.3

0.6 ± 0.2 **

72 ± 10 **

76 ± 13 **

253 ± 64 **

408 ± 80 **

Females (n = 10)

 

 

 

 

 

0 ppm

0.0 ± 0.0

0.1 ± 0.2

14 ± 3

15 ± 4

0 ± 0

0 ± 0

10 ppm

0.0 ± 0.0

0.1 ± 0.1

18 ± 8

17 ± 10

0 ± 0

0 ± 0

50 ppm

0.1 ± 0.2

0.1 ± 0.2

25 ± 10

28 ± 9 *

0 ± 0

7 ± 13

250 ppm

0.3 ± 0.3 **

0.9 ± 0.4 **

79 ± 23 **

80 ± 15 **

362 ± 136 **

450 ± 89 **

Statistics: Anova + Dunnet´s tests: * = P<0.05, ** = P<0.01, two-sided (statistical unit = animal)

Table 2: Absolute (g) and relative (%) body weights and selected organ weights

Males (n = 10)

body weight (abs.) (g)

body weight (rel.) (%)

spleen (abs.) (g)

spleen (rel.) (%)

liver (abs.) (g)

liver (rel.) (%)

adrenal glands (abs.) (g)

adrenal gland (rel.) (%)

0 ppm

409.32 ± 26.35

100

0.784 ± 0.122

0.191 ± 0.021

11.998 ± 1.128

2.927 ± 0.126

0.081 ± 0.008

0.02 ± 0.002

10 ppm

424.87 ± 42.81

100

0.837 ± 0.156

0.196 ± 0.026

13.153 ± 2.522

3.082 ± 0.379

0.091 ± 0.01

0.021 ± 0.002

50 ppm

423.9 ± 36.25

100

0.872 ± 0.165

0.205 ± 0.029

13.261 ± 1.657

3.121 ± 0.151

0.099 ± 0.009 *

0.024 ± 0.003 *

250 ppm

432.93 ± 45.6

100

1.587 ± 0.247 **

0.369 ± 0.066 **

14.236 ± 3.01

3.26 ± 0.373 *

0.094 ± 0.021

0.022 ± 0.003

Females (n = 10)

 

 

 

 

 

 

 

0 ppm

235.16 ± 27.48

100

0.521 ± 0.047

0.223 ± 0.023

7.425 ± 1.004

3.154 ± 0.147

0.013 ± 0.015

0.048 ± 0.009

10 ppm

226.16 ± 15.13

100

0.486 ± 0.066

0.214 ± 0.021

7.149 ± 0.563

3.163 ± 0.171

0.11 ± 0.008

0.049 ± 0.004

50 ppm

237.61 ± 35.95

100

0.536 ± 0.072

0.227 ± 0.025

7.627 ± 1.111

3.215 ± 0.14

0.117 ± 0.015

0.05 ± 0.006

250 ppm

232.35 ± 12.07

100

1.164 ± 0.307 **

0.499 ± 0.124 **

7.533 ± 0.325

3.247 ± 0.154

0.113 ± 0.011

0.049 ± 0.006

Statistics: Dunnet´s test: * = P<0.05, ** = P<0.01, two-sided (statistical unit = animal)

Table 3: Hematology data of selected parameters of control and high dose group on day 36 and 85, respectively

Day 36:

WBC (giga/l)

RBC (tera/l)

HGB (mmol/l)

HCT (l/l)

MCV (fl)

MCH (fmol)

MCHC (mmol/l)

PLT )giga/l)

Males (n = 10)

 

 

 

 

 

 

 

0 ppm

7.06 ± 0.63

8.19 ± 0.36

9.47 ± 0.49

0.416 ± 0.027

50.72 ± 1.21

1.16 ± 0.02

22.77 ± 0.62

1000 ± 96

250 ppm

8.18 ± 1.81

7.14 ± 0.51 **

8.72 ± 0.44 **

0.397 ± 0.024

55.56 ± 2.14 **

1.22 ± 0.05 **

22.00 ± 0.57 *

1017 ± 110

Females (n = 10)

 

 

 

 

 

 

 

0 ppm

4.28 ± 0.72

7.88 ± 0.47

9.16 ± 0.38

0.396 ± 0.021

50.18 ± 1.16

1.16 ± 0.03

23.14 ± 0.58

1136 ± 98

250 ppm

5.88 ± 1.30

6.61 ± 0.44 **

8.40 ± 0.38 **

0.373 ± 0.018

56.50 ± 2.53 **

1.27 ± 0.05 **

22.52 ± 0.53

1093 ± 160

Day 85:

 

 

 

 

 

 

 

 

Males (n = 10)

 

 

 

 

 

 

 

0 ppm

5.87 ± 0.95

8.47 ± 0.54

9.26 ± 0.51

0.414 ± 0.028

48.84 ± 1.03

1.09 ± 0.03

22.38 ± 0.57

1058 ± 111

250 ppm

7.31 ± 1.20

7.44 ± 0.44 **

8.69 ± 0.39 *

0.400 ± 0.020

53.66 ± 1.97 **

1.17 ± 0.05 **

21.74 ± 0.35 **

1101 ± 171

Females (n = 10)

 

 

 

 

 

 

 

0 ppm

3.90 ± 1.39

8.39 ± 0.42

9.29 ± 0.51

0.41 ± 0.021

48.83 ± 1.06

1.11 ± 0.03

22.65 ± 0.52

1114 ± 73

250 ppm

4.30 ± 0.87

6.49 ± 0.48 **

8.08 ± 0.29 **

0.364 ± 0.016 **

56.13 ± 2.00 **

1.25 ± 0.06 **

22.22 ± 0.44

992 ± 159

Statistics: Dunnet´s test: * = P<0.05, ** = P<0.01, two-sided (statistical unit = animal)

Applicant's summary and conclusion